vs

Side-by-side financial comparison of Spero Therapeutics, Inc. (SPRO) and U-BX Technology Ltd. (UBXG). Click either name above to swap in a different company.

Spero Therapeutics, Inc. is the larger business by last-quarter revenue ($12.6M vs $12.4M, roughly 1.0× U-BX Technology Ltd.). Spero Therapeutics, Inc. runs the higher net margin — 250.7% vs -24.7%, a 275.4% gap on every dollar of revenue.

SPRO vs UBXG — Head-to-Head

Bigger by revenue
SPRO
SPRO
1.0× larger
SPRO
$12.6M
$12.4M
UBXG
Higher net margin
SPRO
SPRO
275.4% more per $
SPRO
250.7%
-24.7%
UBXG

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
SPRO
SPRO
UBXG
UBXG
Revenue
$12.6M
$12.4M
Net Profit
$31.5M
$-3.1M
Gross Margin
0.4%
Operating Margin
-22.1%
Net Margin
250.7%
-24.7%
Revenue YoY
24080.8%
Net Profit YoY
250.9%
EPS (diluted)
$0.56
$-0.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SPRO
SPRO
UBXG
UBXG
Q4 25
$12.6M
Q3 25
$0
Q2 25
$0
$12.4M
Q1 25
$12.0K
Q4 24
$52.0K
Q3 24
$65.0K
Q2 24
$114.0K
Q1 24
$140.0K
Net Profit
SPRO
SPRO
UBXG
UBXG
Q4 25
$31.5M
Q3 25
$-7.4M
Q2 25
$-1.7M
$-3.1M
Q1 25
$-13.9M
Q4 24
Q3 24
$-17.1M
Q2 24
$-17.9M
Q1 24
$-12.7M
Gross Margin
SPRO
SPRO
UBXG
UBXG
Q4 25
Q3 25
Q2 25
0.4%
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
SPRO
SPRO
UBXG
UBXG
Q4 25
Q3 25
Q2 25
-22.1%
Q1 25
-122758.3%
Q4 24
Q3 24
-28604.6%
Q2 24
-16720.2%
Q1 24
-9987.1%
Net Margin
SPRO
SPRO
UBXG
UBXG
Q4 25
250.7%
Q3 25
Q2 25
-24.7%
Q1 25
-115550.0%
Q4 24
Q3 24
-26380.0%
Q2 24
-15668.4%
Q1 24
-9049.3%
EPS (diluted)
SPRO
SPRO
UBXG
UBXG
Q4 25
$0.56
Q3 25
$-0.13
Q2 25
$-0.03
$-0.55
Q1 25
$-0.25
Q4 24
Q3 24
$-0.32
Q2 24
$-0.33
Q1 24
$-0.24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SPRO
SPRO
UBXG
UBXG
Cash + ST InvestmentsLiquidity on hand
$40.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$59.0M
$19.0M
Total Assets
$68.9M
$21.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SPRO
SPRO
UBXG
UBXG
Q4 25
$40.3M
Q3 25
$48.6M
Q2 25
$31.2M
Q1 25
$48.9M
Q4 24
$52.9M
Q3 24
$76.3M
Q2 24
$63.5M
Q1 24
$82.3M
Stockholders' Equity
SPRO
SPRO
UBXG
UBXG
Q4 25
$59.0M
Q3 25
$26.5M
Q2 25
$32.8M
$19.0M
Q1 25
$33.8M
Q4 24
$46.1M
Q3 24
$65.5M
Q2 24
$80.5M
Q1 24
$96.2M
Total Assets
SPRO
SPRO
UBXG
UBXG
Q4 25
$68.9M
Q3 25
$54.2M
Q2 25
$62.1M
$21.0M
Q1 25
$77.7M
Q4 24
$110.5M
Q3 24
$135.2M
Q2 24
$149.9M
Q1 24
$167.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SPRO
SPRO
UBXG
UBXG
Operating Cash FlowLast quarter
$-8.4M
$-1.2M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
-0.26×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SPRO
SPRO
UBXG
UBXG
Q4 25
$-8.4M
Q3 25
$17.4M
Q2 25
$-17.7M
$-1.2M
Q1 25
$-4.0M
Q4 24
$-23.4M
Q3 24
$12.8M
Q2 24
$-18.7M
Q1 24
$5.9M
Cash Conversion
SPRO
SPRO
UBXG
UBXG
Q4 25
-0.26×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons